Overview


According to FutureWise analysis the market for allogeneic t cell therapies in 2023 is US$ 1.21 billion, and is expected to reach US$ 1.46 billion by 2031 at a CAGR of 10%.

Allogeneic T-cell therapies refer to immunotherapy that utilizes T cells obtained from healthy donors to treat various diseases, particularly cancer. In this approach, T cells from a donor are collected, processed, and modified, if necessary, to enhance their anti-tumor activity and persistence. These modified T cells are then infused into patients who are in need of treatment. Allogeneic T cell therapies differ from autologous T cell therapies, where T cells are derived from the patient's body. Allogeneic T-cell therapies aim to harness the immune system's power to recognize and destroy cancer cells. When administered to the patient, the infused T cells can target and attack cancer cells, resulting in tumor regression or eradication. Allogeneic T-cell therapies have shown promise in treating various types of cancer, including hematological malignancies (such as leukemia and lymphoma) and solid tumors.

One of the advantages of allogeneic T-cell therapies is their potential for scalability. As T cells can be obtained from healthy donors and expanded in large quantities, these therapies can be manufactured and made readily available to multiple patients. This is in contrast to autologous T cell therapies, where each patient's T cells must be collected and processed individually. The market for allogeneic T-cell therapies has been experiencing significant growth in recent years. The market growth is attributed to numerous factors. Firstly, allogeneic T cell therapies have the advantage of being "off-the-shelf" treatments, meaning they can be manufactured in large quantities and readily available for patients, unlike autologous therapies that require a personalized approach for each patient. This scalability and accessibility make allogeneic T-cell therapies more attractive commercially.

FutureWise Market Research has published a report that provides an insightful analysis of allogeneic t cell therapies market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the allogeneic t cell therapies market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  •  Autolus.
  •  TrakCel
  •  Tmunity Therapeutics
  •  Bellicum Pharmaceuticals Inc.
  •  Sorrento Therapeutics
  •  Bluebird Inc.
  •  Minerva Biotechnologies Corporation
  •  Kite Pharma
  •  CELGENE CORPORATION
  •  Cellectis
  •  Fortress Biotech
  •  Promab Biotechnologies
  •  Immune Therapeutics
  •  Ziopharm Oncology Inc.
  •  Juno Therapeutics
  •  Novartis AG
  •  Celyad
  •  Eureka Therapeutics Inc.
  •  TILT Biotherapeutics
  •  Poseida Therapeutics Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Antigen Type

  •  CD 19
  •  CD 20
  •  Egfrvlll
  •  GD2
  •  CD22
  •  CD30
  •  CD33
  •  Meso
  •  HER1
  •  HER2
  •  Egfrvlll

By Indication

  •  Diffuse Large B-Cell Lymphoma
  •  Multiple Myeloma
  •  Acute Lymphoblastic Leukemia
  •  Chronic Lymphocytic Leukemia
  •  Follicular Lymphoma
  •  Others

By End User

  •  Research Institutes
  •  Biotechnological and pharmaceutical organizations
  •  Diagnostic centers or labs
  •  Academics or educational centers

By Region

  •  North America
  •  Europe
  •  Asia-Pacific
  •  Latin America
  •  Middle East and Africa
  •  Tier 1 players- established companies in the market with a major market share
  •  Tier 2 players
  •  Emerging players which are growing rapidly
  •  New Entrants
  •  Growth prospects
  •  SWOT analysis
  •  Key trends
  •  Key data-points affecting market growth
  •  To provide with an exhaustive analysis on the Allogeneic T Cell Therapies Market By Antigen Type, By Indication, By End user and By Region.
  •  To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  •  To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions
  •  We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  •  The customization Mobility Care offered are free of charge with purchase of any license of the report
  •  You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Allogeneic T Cell Therapies Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Allogeneic T Cell Therapies Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Allogeneic T Cell Therapies Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Allogeneic T Cell Therapies Market, By Antigen Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. CD 19
        2. CD 20
        3. Egfrvlll
        4. GD2
        5. CD22
        6. CD30
        7. CD33
        8. Meso
        9. HER1
          10. HER2
          11. Egfrvlll

  • 8.   Global Allogeneic T Cell Therapies Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Diffuse Large B-Cell Lymphoma
        2. Multiple Myeloma
        3. Acute Lymphoblastic Leukemia
        4. Chronic Lymphocytic Leukemia
        5. Follicular Lymphoma
        6. Others

  • 9.   Global Allogeneic T Cell Therapies Market, By End user Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Research Institutes
        2. Biotechnological and pharmaceutical organizations
        3. Diagnostic centers or labs
        4. Academics or educational centers

  • 10.   North America Allogeneic T Cell Therapies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Allogeneic T Cell Therapies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Allogeneic T Cell Therapies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Allogeneic T Cell Therapies Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Autolus.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. TrakCel
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Tmunity Therapeutics
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Bellicum Pharmaceuticals Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Sorrento Therapeutics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bluebird Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Minerva Biotechnologies Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Kite Pharma
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. CELGENE CORPORATION
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
         10. Cellectis
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
          11. Fortress Biotech
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
          12. Promab Biotechnologies
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
          13. Immune Therapeutics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
          14. Ziopharm Oncology Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
          15. Juno Therapeutics
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
          16. Novartis AG
         16.1. Company Overview
         16.2. Product Portfolio
            16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
          17. Celyad
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
          18. Eureka Therapeutics Inc.
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
          19. TILT Biotherapeutics
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
          20. Poseida Therapeutics Inc.
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients